Notably, USP7 inhibitors strongly inhibited AML cell lines and primary AML cells proliferation in vitro, also independently of TP53 status, and significantly delayed leukemia development in a human MLL-AF9 xenograft mouse model [296]. The gene discussed is USP7; the disease is acute myeloid leukemia.